Medicare's GLP-1 Bridge Went Live on July 1. DPC Physicians Do Not Need Medicare Enrollment to Prescribe Through It.

Industry News by DPC Insider
#GLP-1#Medicare#weight management#DPC prescribing#CMS#obesity treatment
Sources: Medicare GLP-1 Bridge · Information for Providers | Medicare GLP-1 Bridge · Medicare GLP-1 Bridge INFORMATION FOR PRESCRIBERS · GLP-1 Weight-Loss Drug Demonstration Begins July 2026 · Some Medicare beneficiaries can now get popular obesity drugs for $50 a month

Most DPC practices serve at least some patients who are on Medicare. And if the last two years of primary care have established anything, it’s that GLP-1 weight-loss drugs are now among the most requested medications in any primary care office.

On July 1, Medicare began covering three of them for $50 a month through a new federal demonstration called the Medicare GLP-1 Bridge. The part most DPC practices have not seen yet: prescribers do not need to be enrolled in Medicare to write the prescription.

What the Bridge Is

The Medicare GLP-1 Bridge is a two-year demonstration program run by CMS. It covers GLP-1 drugs prescribed specifically for weight management — not for type 2 diabetes or other metabolic conditions — from July 1, 2026, through December 31, 2027.

The program operates entirely outside the regular Medicare Part D benefit. Prescriptions do not route through a patient’s Part D plan. Instead, CMS contracted Humana — already the administrator of Medicare’s Limited Income NET (LI NET) program — to act as a single central processor. Prior authorizations go to Humana. Claims go to Humana. Humana pays the pharmacy directly.

That routing decision is what makes the prescriber enrollment question different than it would be under normal Part D.

Three Drugs, One Copay

Three medications are covered under the Bridge:

  • Wegovy (semaglutide), all formulations
  • Zepbound (tirzepatide), KwikPen formulation only
  • Foundayo (retatrutide), all formulations

All three carry a flat $50 monthly copay for the patient. That $50 does not count toward the patient’s Part D deductible or out-of-pocket maximum. The Bridge runs on its own accounting track.

Who Qualifies as a Patient

Patient eligibility runs on a three-tier BMI framework, according to CMS guidance for providers:

  • BMI ≥ 35 with no additional condition required
  • BMI ≥ 30 with at least one of: heart failure, uncontrolled hypertension, or chronic kidney disease
  • BMI ≥ 27 with at least one of: pre-diabetes (by ADA guidelines), prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease

There is an important nuance on measurement timing: the BMI threshold is evaluated at the time GLP-1 therapy was initiated, not at the time of the prior authorization request. A patient who started Wegovy a year ago with a BMI of 37 and has since lost 30 pounds is still eligible — the prescriber attests to the starting BMI, not the current one. This matters for patients already on GLP-1 therapy through other channels who you might be transitioning to the Bridge.

Patients are excluded from the Bridge if they have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Those conditions have separate GLP-1 coverage pathways through existing Part D. The Bridge is specifically for patients whose GLP-1 need is tied to obesity or cardiovascular risk without those existing metabolic diagnoses.

The Prescriber Question

This is where DPC practices should pay close attention.

Under the standard Medicare Part D framework, prescribers are generally required to be enrolled in Medicare. DPC physicians have historically operated outside that system. Some opt out formally. Others have simply never enrolled because they do not bill Medicare for anything.

The Bridge is structured differently. CMS has confirmed that prescribers do not need to be enrolled in Medicare to write a prescription or submit a prior authorization under the Bridge program. The only restriction is that the prescriber must not appear on the Medicare Preclusion List — a separate designation CMS maintains for providers excluded from Medicare due to fraud-related or disciplinary action.

For most DPC physicians, the Preclusion List is a non-issue. Not being enrolled in Medicare is a structural choice about how a practice operates. Being on the Preclusion List is a different category entirely, one that would have preceded any DPC practice decisions by a significant margin.

How the Prior Authorization Works

The submission process goes through Humana, not through any Medicare plan the patient holds. The general flow, per CMS prescriber guidance:

  1. The prescriber submits a prior authorization request electronically to the Bridge’s central processor
  2. The PA must include attestation that the patient met the BMI criteria at the time therapy was initiated and that the patient is participating in a lifestyle modification program
  3. Once approved, the prescriber writes the prescription to a participating retail or mail-order pharmacy
  4. The pharmacy processes the claim through Humana’s system
  5. The patient pays $50 at the pharmacy

CMS has a dedicated prescriber call center at 855-273-0102 (Monday through Friday, 8 a.m. to 7 p.m. ET) for questions about the PA process or to check the status of a request.

The Lifestyle Modification Requirement

The attestation about lifestyle modification is worth flagging separately. Prescribers must confirm the patient is participating in a program. CMS guidance does not mandate a specific licensed program by name, which leaves room for a structured approach within the practice itself — provided there is documentation that supports the attestation.

This also points to something DPC practices are already doing. The longitudinal, relationship-based model lends itself to the kind of weight management counseling the attestation requires. A documented protocol — regular check-ins, behavioral targets, recorded follow-up — creates both the clinical foundation and the paper trail.

What This Means

For DPC practices with Medicare-age patients who have been asking about GLP-1 medications, the Bridge is a prescribing path that did not exist on June 30. The three-part answer to the most common questions: yes, you might prescribe without Medicare enrollment; yes, your patient pays $50 a month; yes, the prior authorization goes to Humana, not to a Part D plan.

The two-year window is worth noting. The Medicare Rights Center has noted that the Bridge is a demonstration, not a permanent coverage pathway. What comes after December 2027 depends on whether Congress enacts permanent GLP-1 coverage under Medicare. DPC practices that build structured weight management into their clinical model now — with documented counseling, follow-up protocols, and the attestation infrastructure the Bridge requires — are building something that has value regardless of what permanent coverage looks like.

For patients who have been waiting, the program has been running for sixteen days. For DPC physicians who assumed Medicare enrollment was the barrier, the CMS guidance says otherwise.